IL6 and juvenile idiopathic arthritis: Early initiation of methotrexate, with the addition of a biologic disease-modifying antirheumatic drug including an interleukin-6 inhibitor for additional disease control in patients with moderate or high disease activity, is suggested in the JIA ACR guidelines [2, 3].